Ishita Drugs and Industries Limited
Ishita Drugs and Industries Limited (ISHITADR.BO) Stock Competitors & Peer Comparison
See (ISHITADR.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ISHITADR.BO | ₹69.00 | -0.33% | 208.8M | 23.51 | ₹2.97 | N/A |
| MEDPLUS.NS | ₹835.05 | -2.31% | 101.8B | 49.14 | ₹17.27 | N/A |
| MEDPLUS.BO | ₹835.45 | -2.51% | 101.8B | 49.23 | ₹17.23 | N/A |
| GUJTHEM.BO | ₹318.80 | +1.21% | 34.1B | 71.52 | ₹4.38 | +0.21% |
| SHUKRAPHAR.BO | ₹37.45 | -4.15% | 17.6B | -200.40 | -₹0.20 | +0.05% |
| KPL.BO | ₹1,339.30 | -6.82% | 15.2B | 26.87 | ₹54.51 | N/A |
| SASTASUNDR.NS | ₹280.85 | -0.95% | 9B | 34.44 | ₹8.17 | N/A |
| SASTASUNDR.BO | ₹279.60 | -1.20% | 8.9B | 34.23 | ₹8.19 | N/A |
| ANUHPHR.BO | ₹75.34 | -1.01% | 7.8B | 18.62 | ₹4.18 | +1.97% |
| FREDUN.BO | ₹1,646.60 | -0.01% | 7.7B | 23.44 | ₹69.98 | +0.04% |
Stock Comparison
ISHITADR.BO vs MEDPLUS.NS Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, MEDPLUS.NS has a market cap of 101.8B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while MEDPLUS.NS trades at ₹835.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas MEDPLUS.NS's P/E ratio is 49.14. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, ISHITADR.BO is more volatile compared to MEDPLUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check MEDPLUS.NS's competition here
ISHITADR.BO vs MEDPLUS.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, MEDPLUS.BO has a market cap of 101.8B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while MEDPLUS.BO trades at ₹835.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas MEDPLUS.BO's P/E ratio is 49.23. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, ISHITADR.BO is more volatile compared to MEDPLUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check MEDPLUS.BO's competition here
ISHITADR.BO vs GUJTHEM.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, GUJTHEM.BO has a market cap of 34.1B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while GUJTHEM.BO trades at ₹318.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas GUJTHEM.BO's P/E ratio is 71.52. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, ISHITADR.BO is more volatile compared to GUJTHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check GUJTHEM.BO's competition here
ISHITADR.BO vs SHUKRAPHAR.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SHUKRAPHAR.BO has a market cap of 17.6B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SHUKRAPHAR.BO trades at ₹37.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SHUKRAPHAR.BO's P/E ratio is -200.40. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, ISHITADR.BO is less volatile compared to SHUKRAPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check SHUKRAPHAR.BO's competition here
ISHITADR.BO vs KPL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, KPL.BO has a market cap of 15.2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while KPL.BO trades at ₹1,339.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas KPL.BO's P/E ratio is 26.87. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, ISHITADR.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check KPL.BO's competition here
ISHITADR.BO vs SASTASUNDR.NS Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SASTASUNDR.NS trades at ₹280.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SASTASUNDR.NS's P/E ratio is 34.44. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, ISHITADR.BO is more volatile compared to SASTASUNDR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check SASTASUNDR.NS's competition here
ISHITADR.BO vs SASTASUNDR.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SASTASUNDR.BO has a market cap of 8.9B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SASTASUNDR.BO trades at ₹279.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SASTASUNDR.BO's P/E ratio is 34.23. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, ISHITADR.BO is more volatile compared to SASTASUNDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check SASTASUNDR.BO's competition here
ISHITADR.BO vs ANUHPHR.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ANUHPHR.BO has a market cap of 7.8B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ANUHPHR.BO trades at ₹75.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ANUHPHR.BO's P/E ratio is 18.62. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, ISHITADR.BO is more volatile compared to ANUHPHR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check ANUHPHR.BO's competition here
ISHITADR.BO vs FREDUN.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, FREDUN.BO has a market cap of 7.7B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while FREDUN.BO trades at ₹1,646.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas FREDUN.BO's P/E ratio is 23.44. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, ISHITADR.BO is less volatile compared to FREDUN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check FREDUN.BO's competition here
ISHITADR.BO vs BPLPHARMA.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, BPLPHARMA.BO has a market cap of 7.6B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while BPLPHARMA.BO trades at ₹1,095.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas BPLPHARMA.BO's P/E ratio is -25.74. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, ISHITADR.BO is more volatile compared to BPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check BPLPHARMA.BO's competition here
ISHITADR.BO vs PRAVEG.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PRAVEG.BO has a market cap of 6.7B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PRAVEG.BO trades at ₹261.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PRAVEG.BO's P/E ratio is -270.96. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, ISHITADR.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check PRAVEG.BO's competition here
ISHITADR.BO vs SUDARSHAN.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SUDARSHAN.BO has a market cap of 6.6B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SUDARSHAN.BO trades at ₹26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SUDARSHAN.BO's P/E ratio is 32.63. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, ISHITADR.BO is more volatile compared to SUDARSHAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check SUDARSHAN.BO's competition here
ISHITADR.BO vs SGRL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SGRL.BO has a market cap of 6.5B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SGRL.BO trades at ₹518.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SGRL.BO's P/E ratio is 36.14. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, ISHITADR.BO is more volatile compared to SGRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check SGRL.BO's competition here
ISHITADR.BO vs ALBERTDA.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, ISHITADR.BO is more volatile compared to ALBERTDA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check ALBERTDA.BO's competition here
ISHITADR.BO vs VIKRAMTH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, VIKRAMTH.BO has a market cap of 4.7B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while VIKRAMTH.BO trades at ₹151.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas VIKRAMTH.BO's P/E ratio is 13.83. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, ISHITADR.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check VIKRAMTH.BO's competition here
ISHITADR.BO vs JENBURPH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, JENBURPH.BO has a market cap of 4.4B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while JENBURPH.BO trades at ₹996.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas JENBURPH.BO's P/E ratio is 13.55. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, ISHITADR.BO is more volatile compared to JENBURPH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check JENBURPH.BO's competition here
ISHITADR.BO vs TLL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, TLL.BO has a market cap of 3.2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while TLL.BO trades at ₹275.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas TLL.BO's P/E ratio is 21.49. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, ISHITADR.BO is more volatile compared to TLL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check TLL.BO's competition here
ISHITADR.BO vs ZENOTECH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ZENOTECH.BO trades at ₹45.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ZENOTECH.BO's P/E ratio is 82.40. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, ISHITADR.BO is more volatile compared to ZENOTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check ZENOTECH.BO's competition here
ISHITADR.BO vs GENNEX.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, GENNEX.BO has a market cap of 2.7B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while GENNEX.BO trades at ₹11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas GENNEX.BO's P/E ratio is 14.97. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, ISHITADR.BO is more volatile compared to GENNEX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check GENNEX.BO's competition here
ISHITADR.BO vs KERALAYUR.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, KERALAYUR.BO has a market cap of 2.4B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while KERALAYUR.BO trades at ₹218.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas KERALAYUR.BO's P/E ratio is -10.33. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, ISHITADR.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check KERALAYUR.BO's competition here
ISHITADR.BO vs SANJIVIN.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SANJIVIN.BO trades at ₹195.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SANJIVIN.BO's P/E ratio is 32.29. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, ISHITADR.BO is more volatile compared to SANJIVIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check SANJIVIN.BO's competition here
ISHITADR.BO vs BDH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, BDH.BO has a market cap of 2.4B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while BDH.BO trades at ₹421.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas BDH.BO's P/E ratio is 22.66. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, ISHITADR.BO is more volatile compared to BDH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check BDH.BO's competition here
ISHITADR.BO vs TRANSCHEM.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, TRANSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while TRANSCHEM.BO trades at ₹174.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas TRANSCHEM.BO's P/E ratio is 75.44. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is less volatile compared to TRANSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check TRANSCHEM.BO's competition here
ISHITADR.BO vs SYSCHEM.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SYSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SYSCHEM.BO trades at ₹50.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SYSCHEM.BO's P/E ratio is 33.75. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, ISHITADR.BO is less volatile compared to SYSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check SYSCHEM.BO's competition here
ISHITADR.BO vs AMBALALSA.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, AMBALALSA.BO has a market cap of 2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while AMBALALSA.BO trades at ₹26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas AMBALALSA.BO's P/E ratio is 21.06. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, ISHITADR.BO is more volatile compared to AMBALALSA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check AMBALALSA.BO's competition here
ISHITADR.BO vs OXYGENTAPH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, OXYGENTAPH.BO has a market cap of 2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while OXYGENTAPH.BO trades at ₹50.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas OXYGENTAPH.BO's P/E ratio is -11.24. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, ISHITADR.BO is more volatile compared to OXYGENTAPH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check OXYGENTAPH.BO's competition here
ISHITADR.BO vs AUROLAB.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, AUROLAB.BO has a market cap of 1.8B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while AUROLAB.BO trades at ₹293.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas AUROLAB.BO's P/E ratio is 57.14. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, ISHITADR.BO is more volatile compared to AUROLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check AUROLAB.BO's competition here
ISHITADR.BO vs KIMIABL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, KIMIABL.BO has a market cap of 1.6B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while KIMIABL.BO trades at ₹30.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, ISHITADR.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check KIMIABL.BO's competition here
ISHITADR.BO vs NATCAPSUQ.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, NATCAPSUQ.BO has a market cap of 1.6B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while NATCAPSUQ.BO trades at ₹156.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas NATCAPSUQ.BO's P/E ratio is -13.32. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, ISHITADR.BO is more volatile compared to NATCAPSUQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check NATCAPSUQ.BO's competition here
ISHITADR.BO vs CORALAB.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, CORALAB.BO has a market cap of 1.6B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while CORALAB.BO trades at ₹430.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas CORALAB.BO's P/E ratio is 9.04. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, ISHITADR.BO is more volatile compared to CORALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check CORALAB.BO's competition here
ISHITADR.BO vs PARNAXLAB.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PARNAXLAB.BO trades at ₹130.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PARNAXLAB.BO's P/E ratio is 13.46. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, ISHITADR.BO is more volatile compared to PARNAXLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check PARNAXLAB.BO's competition here
ISHITADR.BO vs PANCHSHEEL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PANCHSHEEL.BO has a market cap of 1.4B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PANCHSHEEL.BO trades at ₹110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PANCHSHEEL.BO's P/E ratio is 11.97. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, ISHITADR.BO is more volatile compared to PANCHSHEEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check PANCHSHEEL.BO's competition here
ISHITADR.BO vs SMRUTHIORG.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SMRUTHIORG.BO has a market cap of 1.3B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SMRUTHIORG.BO trades at ₹112.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SMRUTHIORG.BO's P/E ratio is 27.78. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, ISHITADR.BO is less volatile compared to SMRUTHIORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check SMRUTHIORG.BO's competition here
ISHITADR.BO vs LACTOSE.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, LACTOSE.BO has a market cap of 1.2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while LACTOSE.BO trades at ₹96.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas LACTOSE.BO's P/E ratio is 42.19. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, ISHITADR.BO is more volatile compared to LACTOSE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check LACTOSE.BO's competition here
ISHITADR.BO vs TYCHE.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, TYCHE.BO has a market cap of 1.2B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while TYCHE.BO trades at ₹117.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas TYCHE.BO's P/E ratio is 12.36. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, ISHITADR.BO is more volatile compared to TYCHE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check TYCHE.BO's competition here
ISHITADR.BO vs PHARMAID.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PHARMAID.BO trades at ₹33.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PHARMAID.BO's P/E ratio is -8.82. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, ISHITADR.BO is more volatile compared to PHARMAID.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check PHARMAID.BO's competition here
ISHITADR.BO vs DENISCHEM.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, DENISCHEM.BO has a market cap of 1B. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while DENISCHEM.BO trades at ₹76.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas DENISCHEM.BO's P/E ratio is 14.66. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, ISHITADR.BO is more volatile compared to DENISCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check DENISCHEM.BO's competition here
ISHITADR.BO vs MERCURYLAB.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, MERCURYLAB.BO has a market cap of 969.7M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while MERCURYLAB.BO trades at ₹801.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas MERCURYLAB.BO's P/E ratio is 20.53. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, ISHITADR.BO is more volatile compared to MERCURYLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check MERCURYLAB.BO's competition here
ISHITADR.BO vs MAKERSL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, MAKERSL.BO has a market cap of 916.6M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while MAKERSL.BO trades at ₹141.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas MAKERSL.BO's P/E ratio is 75.41. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, ISHITADR.BO is more volatile compared to MAKERSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check MAKERSL.BO's competition here
ISHITADR.BO vs SOURCENTRL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SOURCENTRL.BO has a market cap of 808.2M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SOURCENTRL.BO trades at ₹132.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SOURCENTRL.BO's P/E ratio is 27.18. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, ISHITADR.BO is less volatile compared to SOURCENTRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check SOURCENTRL.BO's competition here
ISHITADR.BO vs CONCORD.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, CONCORD.BO has a market cap of 776.7M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while CONCORD.BO trades at ₹76.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas CONCORD.BO's P/E ratio is 134.59. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, ISHITADR.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check CONCORD.BO's competition here
ISHITADR.BO vs BIBCL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, BIBCL.BO has a market cap of 762.1M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while BIBCL.BO trades at ₹17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas BIBCL.BO's P/E ratio is -4.86. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, ISHITADR.BO is more volatile compared to BIBCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check BIBCL.BO's competition here
ISHITADR.BO vs BACPHAR.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, BACPHAR.BO has a market cap of 703.2M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while BACPHAR.BO trades at ₹50.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas BACPHAR.BO's P/E ratio is 132.41. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check BACPHAR.BO's competition here
ISHITADR.BO vs SUNLOC.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SUNLOC.BO has a market cap of 670.1M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SUNLOC.BO trades at ₹65.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SUNLOC.BO's P/E ratio is 23.42. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is less volatile compared to SUNLOC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check SUNLOC.BO's competition here
ISHITADR.BO vs PHRMASI.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PHRMASI.BO has a market cap of 622.2M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PHRMASI.BO trades at ₹96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PHRMASI.BO's P/E ratio is 3.51. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, ISHITADR.BO is more volatile compared to PHRMASI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check PHRMASI.BO's competition here
ISHITADR.BO vs GODAVARI.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, GODAVARI.BO has a market cap of 585.8M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while GODAVARI.BO trades at ₹80.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas GODAVARI.BO's P/E ratio is -85.48. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, ISHITADR.BO is more volatile compared to GODAVARI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check GODAVARI.BO's competition here
ISHITADR.BO vs PANJON.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PANJON.BO has a market cap of 486.4M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PANJON.BO trades at ₹29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PANJON.BO's P/E ratio is 113.36. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, ISHITADR.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check PANJON.BO's competition here
ISHITADR.BO vs VISTAPH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, VISTAPH.BO has a market cap of 425.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while VISTAPH.BO trades at ₹7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas VISTAPH.BO's P/E ratio is -6.06. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, ISHITADR.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check VISTAPH.BO's competition here
ISHITADR.BO vs VRL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, VRL.BO has a market cap of 416.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while VRL.BO trades at ₹125.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas VRL.BO's P/E ratio is 11.14. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to VRL.BO's ROE of +0.10%. Regarding short-term risk, ISHITADR.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check VRL.BO's competition here
ISHITADR.BO vs SHELTER.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SHELTER.BO has a market cap of 415.7M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SHELTER.BO trades at ₹35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SHELTER.BO's P/E ratio is 6.64. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, ISHITADR.BO is less volatile compared to SHELTER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check SHELTER.BO's competition here
ISHITADR.BO vs VEERHEALTH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, VEERHEALTH.BO has a market cap of 399.4M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while VEERHEALTH.BO trades at ₹19.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas VEERHEALTH.BO's P/E ratio is 83.21. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is more volatile compared to VEERHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check VEERHEALTH.BO's competition here
ISHITADR.BO vs ROOPAIND.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ROOPAIND.BO has a market cap of 352M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ROOPAIND.BO trades at ₹42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ROOPAIND.BO's P/E ratio is 18.27. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, ISHITADR.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check ROOPAIND.BO's competition here
ISHITADR.BO vs SANDUPHQ.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SANDUPHQ.BO has a market cap of 341.8M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SANDUPHQ.BO trades at ₹36.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SANDUPHQ.BO's P/E ratio is 21.06. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, ISHITADR.BO is less volatile compared to SANDUPHQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check SANDUPHQ.BO's competition here
ISHITADR.BO vs MEDICAPQ.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, MEDICAPQ.BO has a market cap of 318.9M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while MEDICAPQ.BO trades at ₹24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas MEDICAPQ.BO's P/E ratio is -7.31. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, ISHITADR.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check MEDICAPQ.BO's competition here
ISHITADR.BO vs DECCAN.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, DECCAN.BO has a market cap of 309.5M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while DECCAN.BO trades at ₹13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas DECCAN.BO's P/E ratio is 23.18. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, ISHITADR.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check DECCAN.BO's competition here
ISHITADR.BO vs ANG.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ANG.BO has a market cap of 308.8M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ANG.BO trades at ₹23.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ANG.BO's P/E ratio is -2.53. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, ISHITADR.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check ANG.BO's competition here
ISHITADR.BO vs GUJTERC.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, GUJTERC.BO has a market cap of 294.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while GUJTERC.BO trades at ₹39.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas GUJTERC.BO's P/E ratio is -21.21. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, ISHITADR.BO is less volatile compared to GUJTERC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check GUJTERC.BO's competition here
ISHITADR.BO vs CRSTCHM.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, CRSTCHM.BO has a market cap of 273M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while CRSTCHM.BO trades at ₹91.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas CRSTCHM.BO's P/E ratio is 13.48. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, ISHITADR.BO is more volatile compared to CRSTCHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check CRSTCHM.BO's competition here
ISHITADR.BO vs TRIMURTHI.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check TRIMURTHI.BO's competition here
ISHITADR.BO vs ASRL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ASRL.BO has a market cap of 218.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ASRL.BO trades at ₹7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ASRL.BO's P/E ratio is 12.85. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, ISHITADR.BO is more volatile compared to ASRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check ASRL.BO's competition here
ISHITADR.BO vs CHEMOPH.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, ISHITADR.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check CHEMOPH.BO's competition here
ISHITADR.BO vs ZENITHHE.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ZENITHHE.BO has a market cap of 177.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ZENITHHE.BO trades at ₹3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ZENITHHE.BO's P/E ratio is -330.00. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, ISHITADR.BO is more volatile compared to ZENITHHE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check ZENITHHE.BO's competition here
ISHITADR.BO vs NORRIS.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, NORRIS.BO has a market cap of 138.9M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while NORRIS.BO trades at ₹13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, ISHITADR.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check NORRIS.BO's competition here
ISHITADR.BO vs ZENLABS.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ZENLABS.BO has a market cap of 135.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ZENLABS.BO trades at ₹19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ZENLABS.BO's P/E ratio is -7.32. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, ISHITADR.BO is more volatile compared to ZENLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check ZENLABS.BO's competition here
ISHITADR.BO vs EMMESSA.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, EMMESSA.BO has a market cap of 134.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while EMMESSA.BO trades at ₹25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas EMMESSA.BO's P/E ratio is 61.11. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check EMMESSA.BO's competition here
ISHITADR.BO vs CHCL.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while CHCL.BO trades at ₹5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, ISHITADR.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check CHCL.BO's competition here
ISHITADR.BO vs DESHRAK.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, DESHRAK.BO has a market cap of 113.7M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while DESHRAK.BO trades at ₹25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas DESHRAK.BO's P/E ratio is 30.90. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check DESHRAK.BO's competition here
ISHITADR.BO vs PARMAX.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PARMAX.BO has a market cap of 113.7M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PARMAX.BO trades at ₹30.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PARMAX.BO's P/E ratio is -3.90. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PARMAX.BO's ROE of +2.05%. Regarding short-term risk, ISHITADR.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check PARMAX.BO's competition here
ISHITADR.BO vs COLINZ.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, COLINZ.BO has a market cap of 113.6M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while COLINZ.BO trades at ₹47.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas COLINZ.BO's P/E ratio is 23.01. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, ISHITADR.BO is more volatile compared to COLINZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check COLINZ.BO's competition here
ISHITADR.BO vs SHAMROIN.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, SHAMROIN.BO has a market cap of 110.6M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while SHAMROIN.BO trades at ₹20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas SHAMROIN.BO's P/E ratio is -22.89. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, ISHITADR.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check SHAMROIN.BO's competition here
ISHITADR.BO vs TRINITYLEA.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, TRINITYLEA.BO has a market cap of 110.4M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while TRINITYLEA.BO trades at ₹14.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas TRINITYLEA.BO's P/E ratio is -465.00. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, ISHITADR.BO is less volatile compared to TRINITYLEA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check TRINITYLEA.BO's competition here
ISHITADR.BO vs BERLDRG.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, BERLDRG.BO has a market cap of 110.3M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while BERLDRG.BO trades at ₹21.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas BERLDRG.BO's P/E ratio is 725.00. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, ISHITADR.BO is more volatile compared to BERLDRG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check BERLDRG.BO's competition here
ISHITADR.BO vs VIVANZA.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, VIVANZA.BO has a market cap of 83.2M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while VIVANZA.BO trades at ₹2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas VIVANZA.BO's P/E ratio is -26.00. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, ISHITADR.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check VIVANZA.BO's competition here
ISHITADR.BO vs ADLINE.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, ADLINE.BO has a market cap of 82M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while ADLINE.BO trades at ₹14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, ISHITADR.BO is less volatile compared to ADLINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check ADLINE.BO's competition here
ISHITADR.BO vs HINDBIO.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, HINDBIO.BO has a market cap of 82M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while HINDBIO.BO trades at ₹8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas HINDBIO.BO's P/E ratio is 53.33. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, ISHITADR.BO is more volatile compared to HINDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check HINDBIO.BO's competition here
ISHITADR.BO vs EVOQ.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, EVOQ.BO has a market cap of 80.2M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while EVOQ.BO trades at ₹3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas EVOQ.BO's P/E ratio is 4.54. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is less volatile compared to EVOQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check EVOQ.BO's competition here
ISHITADR.BO vs DECIPHER.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, DECIPHER.BO has a market cap of 75.8M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while DECIPHER.BO trades at ₹7.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas DECIPHER.BO's P/E ratio is -0.94. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to DECIPHER.BO's ROE of -0.38%. Regarding short-term risk, ISHITADR.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check DECIPHER.BO's competition here
ISHITADR.BO vs GANGAPHARM.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, ISHITADR.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check GANGAPHARM.BO's competition here
ISHITADR.BO vs TIAANC.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, TIAANC.BO has a market cap of 63.2M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while TIAANC.BO trades at ₹6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas TIAANC.BO's P/E ratio is -61.50. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, ISHITADR.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check TIAANC.BO's competition here
ISHITADR.BO vs KOBO.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, KOBO.BO has a market cap of 59.6M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while KOBO.BO trades at ₹2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas KOBO.BO's P/E ratio is -1.18. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, ISHITADR.BO is more volatile compared to KOBO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check KOBO.BO's competition here
ISHITADR.BO vs PATIDAR.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, PATIDAR.BO has a market cap of 51.9M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while PATIDAR.BO trades at ₹9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas PATIDAR.BO's P/E ratio is -19.24. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, ISHITADR.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check PATIDAR.BO's competition here
ISHITADR.BO vs WELCURE.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, WELCURE.BO has a market cap of 36M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while WELCURE.BO trades at ₹0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas WELCURE.BO's P/E ratio is 1.10. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, ISHITADR.BO is more volatile compared to WELCURE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check WELCURE.BO's competition here
ISHITADR.BO vs TMTIND-B1.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, TMTIND-B1.BO has a market cap of 34.5M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while TMTIND-B1.BO trades at ₹6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas TMTIND-B1.BO's P/E ratio is -7.83. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, ISHITADR.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ISHITADR.BO.Check TMTIND-B1.BO's competition here
ISHITADR.BO vs FABINO.BO Comparison February 2026
ISHITADR.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISHITADR.BO stands at 208.8M. In comparison, FABINO.BO has a market cap of 27.5M. Regarding current trading prices, ISHITADR.BO is priced at ₹69.00, while FABINO.BO trades at ₹13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISHITADR.BO currently has a P/E ratio of 23.51, whereas FABINO.BO's P/E ratio is -17.95. In terms of profitability, ISHITADR.BO's ROE is +0.08%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, ISHITADR.BO is less volatile compared to FABINO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ISHITADR.BO.Check FABINO.BO's competition here